{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:15:24Z","timestamp":1791134124510,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T00:00:00Z","timestamp":1583971200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Ineffective antibiotic therapy increases mortality of acute cholangitis. The choice of antibiotics should reflect local resistance patterns and avoid the overuse of broad-spectrum agents. In this study, we analysed how results of bile and blood cultures and patient data can be used for selection of empirical antibiotic therapy in acute cholangits.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Pathogen frequencies and susceptibility rates were determined in 423 positive bile duct cultures and 197 corresponding blood cultures obtained from 348 consecutive patients with acute cholangitis. Patient data were retrieved from the medical records. Associations of patient and microbiological data were assessed using the Chi-2 test and multivariate binary logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In bile cultures, enterobacterales and enterococci were isolated with equal frequencies of approximately 30% whereas in blood cultures, enterobacterales predominated (56% compared to 21% enterococci). Antibiotic resistance rates of enterobacterales were\u2009&gt;\u200920% for fluorochinolones, cephalosporines and acylureidopenicillins but not for carbapenems (&lt;\u20092%). The efficacy of empirical therapy was poor with a coverage of bacterial bile and blood culture isolates in 51 and 69%, respectively. By multivariate analysis, predictors for pathogen species, antibiotic susceptibility and expected antibiotic coverage were identified.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In unselected patients treated for acute cholangitis in a large tertiary refferential center, use of carbapenems seems necessary to achieve a high antibiotic coverage. However, by analysis of patient and microbiological data, subgroups for highly effective carbapenem-sparing therapy can be defined. For patients with community-acquired cholangitis without biliary prosthesis who do not need intensive care, piperacillin\/tazobactam represents a regimen with an expected excellent antibiotic coverage.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12876-020-01201-6","type":"journal-article","created":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T01:40:42Z","timestamp":1583977242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Use of microbiological and patient data for choice of empirical antibiotic therapy in acute cholangitis"],"prefix":"10.1186","volume":"20","author":[{"given":"Tassilo","family":"Kruis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"G\u00fcse-Jaschuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Siegmund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00f6rg","family":"Epple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,12]]},"reference":[{"issue":"9","key":"1201_CR1","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/nrgastro.2009.126","volume":"6","author":"JG Lee","year":"2009","unstructured":"Lee JG. Diagnosis and management of acute cholangitis. Nat Rev Gastroenterol Hepatol. 2009;6(9):533\u201341.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"6","key":"1201_CR2","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/jhbp.452","volume":"24","author":"H Gomi","year":"2017","unstructured":"Gomi H, Takada T, Hwang TL, Akazawa K, Mori R, Endo I, et al. Updated comprehensive epidemiology, microbiology, and outcomes among patients with acute cholangitis. J Hepatobiliary Pancreat Sci. 2017;24(6):310\u20138.","journal-title":"J Hepatobiliary Pancreat Sci."},{"issue":"6","key":"1201_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1093\/jac\/dks062","volume":"67","author":"M Ortega","year":"2012","unstructured":"Ortega M, Marco F, Soriano A, Almela M, Mart\u00ednez JA, L\u00f3pez J, et al. Epidemiology and prognostic determinants of bacteraemic biliary tract infection. J Antimicrob Chemother. 2012;67(6):1508\u201313.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"1201_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jhbp.518","volume":"25","author":"H Gomi","year":"2018","unstructured":"Gomi H, Solomkin Joseph S, Schlossberg D, et al. Tokyo guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci. 2018;25(1):3\u201316.","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"1201_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3390\/ph6111335","volume":"6","author":"I Morrissey","year":"2013","unstructured":"Morrissey I, Hackel M, Badal R, Bouchillon S, Hawser S, Biedenbach D. A review of ten years of the Study for Monitoring Antimicrobial Resistance Trends (SMART) from 2002 to 2011. Pharmaceuticals. 2013;6:1335\u201346.","journal-title":"Pharmaceuticals"},{"key":"1201_CR6","doi-asserted-by":"crossref","unstructured":"Hygienema\u00dfnahmen bei Infektionen oder Besiedlung mit multiresistenten gramnegativen St\u00e4bchen. Bundesgesundheitsblatt. 2012;55:1311\u201354.","DOI":"10.1007\/s00103-012-1549-5"},{"issue":"2","key":"1201_CR7","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.gie.2010.02.043","volume":"72","author":"AA Negm","year":"2010","unstructured":"Negm AA, Schott A, Vonberg RP, Weismueller TJ, Schneider AS, Kubicka S, et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc. 2010;72(2):284\u201391.","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"1201_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5946\/ce.2012.45.2.155","volume":"45","author":"JC Goo","year":"2012","unstructured":"Goo JC, Hyuk Seong M, Kwang Shim Y, Seung Lee H, Han JH, Seob Shin K, et al. Extended spectrum-\u03b2-lactamase or carbapenemase producing bacteria isolated from patients with acute cholangitis. Clin Endosc. 2012;45(2):155\u201360.","journal-title":"Clin Endosc"},{"issue":"2","key":"1201_CR9","first-page":"111","volume":"67","author":"A Weber","year":"2013","unstructured":"Weber A, Schneider J, Wagenpfeil S, Winkle P, Riedel J, Wantia N, et al. Spectrum of pathogens in acute cholangitis in patients with and without biliary endoprosthesis. J Inf Secur. 2013;67(2):111\u201321.","journal-title":"J Inf Secur"},{"issue":"1","key":"1201_CR10","doi-asserted-by":"publisher","first-page":"e0169900","DOI":"10.1371\/journal.pone.0169900","volume":"12","author":"Philipp A. Reuken","year":"2017","unstructured":"Reuken PA, Torres D, Baier M, L\u00f6ffler B, L\u00fcbbert C, Lippmann N, et al. Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS ONE. 2017;12(1):e0169900.","journal-title":"PLOS ONE"},{"issue":"10","key":"1201_CR11","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1128\/JCM.27.10.2373-2375.1989","volume":"27","author":"I Brook","year":"1989","unstructured":"Brook I. Aerobic and anaerobic microbiology of biliary tract disease. J Clin Microbiol. 1989;27(10):2373\u20135.","journal-title":"J Clin Microbiol"},{"issue":"10","key":"1201_CR12","doi-asserted-by":"publisher","first-page":"e110112","DOI":"10.1371\/journal.pone.0110112","volume":"9","author":"Jochen Schneider","year":"2014","unstructured":"Schneider J, Hapfelmeier A, Fremd J, Schenk P, Obermeier A, Burgkart R, et al. Biliary endoprosthesis: A prospective analysis of bacterial colonization and risk factors for sludge formation. PLoS One. 2014;9(10).","journal-title":"PLoS ONE"},{"issue":"5","key":"1201_CR13","doi-asserted-by":"publisher","first-page":"e0155479","DOI":"10.1371\/journal.pone.0155479","volume":"11","author":"Christoph L\u00fcbbert","year":"2016","unstructured":"L\u00fcbbert C, Wendt K, Feisthammel J, Moter A, Lippmann N, Busch T, et al. Epidemiology and resistance patterns of bacterial and fungal colonization of biliary plastic stents: A prospective cohort study. PLoS One. 2016;11(5).","journal-title":"PLOS ONE"},{"key":"1201_CR14","unstructured":"Bundesamt fur Verbraucherschutz und Lebensmittelsicherheit, Paul-Ehrlich-Gesellschaft fur Chemotherapie e.V. GERMAP 2015 \u2013 Bericht uber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterinarmedizin in Deutschland. Antiinfectives Intelligence, Rheinbach, 2016."},{"issue":"10","key":"1201_CR15","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1001\/jama.2018.12163","volume":"320","author":"PNA Harris","year":"2018","unstructured":"Harris PNA, Tambyah PA, Lye DC, Mo Y, Lee TH, Yilmaz M, et al. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with e coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance. JAMA. 2018;320(10):984\u201394.","journal-title":"JAMA"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12876-020-01201-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-020-01201-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T19:33:35Z","timestamp":1615491215000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-020-01201-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,12]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1201"],"URL":"https:\/\/doi.org\/10.1186\/s12876-020-01201-6","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,12]]},"assertion":[{"value":"11 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the internal review board (local ethics committee of Charit\u00e9 \u2013 Universit\u00e4tmedizin Berlin; registry number EA2\/033\/16). The need for informed consent was waived for this retrospective study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}